<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3004233565
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        REPATHA 140 mg/ml Solution For Injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        EVOLOCUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        140
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1758.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AMGEN MANUFACTURING LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AMGEN MANUFACTURING LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AMGEN EUROPE B.V.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AX13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Repatha is and how it works</strong></p><p>&nbsp;</p><p>Repatha is a medicine that lowers levels of &lsquo;bad&rsquo; cholesterol, a type of fat, in the blood.</p><p>&nbsp;</p><p>Repatha contains the active substance evolocumab, a monoclonal antibody (a type of specialised protein designed to attach to a target substance in the body). Evolocumab is designed to attach to a substance called PCSK9 that affects the liver&rsquo;s ability to take in cholesterol. By attaching to, and mopping up PCSK9, the medicine increases the amount of cholesterol entering the liver and so lowers the level of cholesterol in the blood.</p><p>&nbsp;</p><p>What Repatha is used for</p><p>&nbsp;</p><p>Repatha is used in addition to your cholesterol lowering diet if you are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an adult with a high cholesterol level in your blood (primary hypercholesterolaemia [heterozygous familial and non-familial] or mixed dyslipidaemia). It is given:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; together with a statin or other cholesterol lowering medication, if the maximum dose of a statin does not lower levels of cholesterol sufficiently.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alone or together with other cholesterol lowering medications when statins do not work well or cannot be used.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a child aged 10&nbsp;years and older with a high cholesterol level in your blood because of a condition that runs in your family (heterozygous familial hypercholesterolaemia or HeFH). It is given alone or together with other cholesterol lowering treatments.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an adult or a child aged 10&nbsp;&nbsp;years and older with a high cholesterol level in your blood because of a condition that runs in your family (homozygous familial hypercholesterolaemia or HoFH). It is given together with other cholesterol lowering treatments.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an adult with a high cholesterol level in your blood and established atherosclerotic cardiovascular disease (a history of heart attack, stroke or blood vessel problems). It is given:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; together with a statin or other cholesterol lowering medication, if the maximum dose of a statin does not lower levels of cholesterol sufficiently.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alone or together with other cholesterol lowering medications when statins do not work well or cannot be used.</p><p>&nbsp;</p><p>Repatha is used in patients who cannot control their cholesterol levels with a cholesterol lowering diet alone. You should stay on your cholesterol lowering diet while taking this medicine. Repatha can help prevent heart attack, stroke, and certain heart procedures to restore blood flow to the heart due to a build-up of fatty deposits in your arteries (also known as atherosclerotic cardiovascular disease).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Repatha</strong> if you are allergic to evolocumab or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>Talk to your doctor, pharmacist or nurse before using Repatha if you have liver disease.</p><p>&nbsp;</p><p>The needle cover of the glass pre-filled pen is made from dry natural rubber (a derivative of latex), which may cause severe allergic reactions.</p><p>&nbsp;</p><p>In order to improve the traceability of this medicine, your doctor or pharmacist should record the name and the lot number of the product you have been given in your patient file. You may also wish to make a note of these details in case you are asked for this information in the future.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p><strong>&nbsp;</strong></p><p>The use of Repatha has been studied in children 10&nbsp;years of age and older being treated for heterozygous or homozygous familial hypercholesterolaemia.</p><p>&nbsp;</p><p>The use of Repatha has not been studied in children under 10&nbsp;years of age.</p><p>&nbsp;</p><p><strong>Other medicines and Repatha</strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Repatha has not been tested in pregnant women. It is not known if Repatha will harm your unborn baby.</p><p>&nbsp;</p><p>It is not known whether Repatha is found in breast milk.</p><p>&nbsp;</p><p>It is important to tell your doctor if you are breast-feeding or plan to do so. Your doctor will then help you decide whether to stop breast-feeding, or whether to stop taking Repatha, considering the benefit of breast‑feeding to the baby and the benefit of Repatha to the mother.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>Repatha has no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p><p><strong>Repatha contains sodium</strong></p><p>&nbsp;</p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>&nbsp;</p><p>The recommended dose depends on the underlying condition:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for adults with primary hypercholesterolaemia and mixed dyslipidaemia the dose is either 140&nbsp;mg every two weeks or 420&nbsp;mg once monthly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for children aged 10&nbsp;years or older with heterozygous familial hypercholesterolaemia the dose is either 140&nbsp;mg every two weeks or 420&nbsp;mg once monthly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for adults or children aged 10 years or older with homozygous familial hypercholesterolaemia the recommended starting dose is 420&nbsp;mg once monthly. After 12&nbsp;weeks your doctor may decide to increase the dose to 420&nbsp;mg every two weeks. If you also receive apheresis, a procedure similar to dialysis where cholesterol and other fats are removed from the blood, your doctor may decide to start you on a dose of 420&nbsp;mg every two weeks to coincide with your apheresis treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for adults with established atherosclerotic cardiovascular disease (a history of heart attack, stroke or blood vessel problems) the dose is either 140&nbsp;mg every two weeks or 420&nbsp;mg once monthly.</p><p>&nbsp;</p><p>Repatha is given as an injection under the skin (subcutaneous).</p><p>&nbsp;</p><p>If your doctor prescribes a dose of 420&nbsp;mg you must use three pre-filled pens because each pre-filled pen only contains 140&nbsp;mg of medicine. After reaching room temperature, all injections should be given within a 30&nbsp;minute period.</p><p>&nbsp;</p><p>If your doctor decides that you or a caregiver can give the injections of Repatha, you or your caregiver should receive training on how to prepare and inject Repatha correctly. Do not try to inject Repatha until you have been shown how to do it by your doctor or nurse.</p><p>&nbsp;</p><p>See the detailed &ldquo;Instructions for Use&rdquo; at the end of this leaflet for instructions about how to store, prepare, and give your Repatha injections at home. If using the pre-filled pen, <strong>place the correct (yellow) end of the pen on the skin before injecting.</strong></p><p>&nbsp;</p><p>Before starting Repatha, you should be on a diet to lower your cholesterol. You should keep on this cholesterol lowering diet while taking Repatha.</p><p>&nbsp;</p><p>If your doctor has prescribed Repatha along with another cholesterol lowering medicine, follow your doctor&rsquo;s instructions on how to take these medicines together. In this case, please read the dosage instructions in the package leaflet of that particular medicine as well.</p><p>&nbsp;</p><p><strong>If you use more Repatha than you should</strong></p><p><em>&nbsp;</em></p><p>Contact your doctor or pharmacist immediately.</p><p><em>&nbsp;</em></p><p><strong>If you forget to take Repatha</strong></p><p><strong>&nbsp;</strong></p><p>Take Repatha as soon as you can after the missed dose. Then, contact your doctor who will tell you when you should schedule your next dose, and follow the new schedule exactly as your doctor has told you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Common (may affect up to&nbsp;1 in 10&nbsp;people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu (high temperature, sore throat, runny nose, cough and chills)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common cold, such as runny nose, sore throat or sinus infections (nasopharyngitis or upper respiratory tract infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Back pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain (arthralgia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site reactions, such as bruising, redness, bleeding, pain or swelling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions including rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to&nbsp;1 in 100&nbsp;people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives, red itchy bumps on your skin (urticaria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu-like symptoms</p><p>&nbsp;</p><p><strong>Rare (may affect up to&nbsp;1 in&nbsp;1,000 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, mouth, tongue, or throat (angioedema)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C&ndash;8&deg;C). Do not freeze.</p><p>Store in the original carton in order to protect from light.</p><p>&nbsp;</p><p>Your pre-filled pen may be left outside the refrigerator to reach room temperature (up to 25&deg;C) before injection. This will make the injection more comfortable. After removal from the refrigerator, Repatha may be stored at room temperature (up to 25&deg;C) in the original carton and must be used within 1&nbsp;month.</p><p>&nbsp;</p><p>Do not use this medicine if you notice it is discoloured or contains large lumps, flakes or coloured particles.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste.</p><p>&nbsp;</p><p>Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Repatha contains</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is evolocumab. Each SureClick pre-filled pen contains 140&nbsp;mg of evolocumab in 1&nbsp;mL of solution.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: proline (25&nbsp;mg), glacial acetic acid (1.2&nbsp;mg), polysorbate&nbsp;80 (0.10&nbsp;mg), sodium hydroxide, water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What Repatha looks like and contents of the pack
	
Repatha is a solution which is clear to opalescent, colourless to yellowish, and practically free from particles.
	
	Each pack contains one, two, three or six single use SureClick pre-filled pens.
	Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Site of Manufacture of the Drug Product:</strong></p><p>Amgen Manufacturing Limited</p><p>State Road 31</p><p>Kilometer 24.6</p><p>Juncos 00777-4060</p><p>Puerto Rico</p><p>USA</p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder and Manufacturer:</strong></p><p>Amgen Europe B.V.</p><p>Minervum 7061</p><p>4817 ZK Breda</p><p>The Netherlands</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in April 2022.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو ريباثا وما هي طريقة عمله</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">ريباثا هو عبارة عن دواء يخفض مستويات الكولسترول &quot;السيء&quot;، وهو نوع من الدهون، في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي ريباثا على المادة الفعالة إفولوكوماب وهو جسم مضاد أحادي النسيلة (نوع من البروتينات مصمم للارتباط بمواد مستهدفة في الجسم). صمم إفولوكوماب لكي يرتبط بمادة اسمها PCSK9 وهي تؤثر على قدرة الكبد على التقاط الكولسترول. من خلال ارتباط الجسم المضاد بمادة PCSK9 وإزالتها، يزيد هذا الدواء من كمية الكولسترول التي تدخل الكبد وبالتالي يقلل من مستوى الكولسترول في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ما هي استخدامات ريباثا</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم ريباثا إلى جانب نظامك الغذائي الخافض للكولسترول إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت من البالغين وكان مستوى كولسترول دمك مرتفعا (أي لديك ارتفاع الكولسترول الأولي في الدم [العائلي مختلف الأمشاج أو الغير عائلي] أو خلل في كمية الدهون المختلطة في الدم). ويتم إعطاؤه:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع دواء ستاتيني أو دواء آخر من الأدوية الخافضة للكولسترول، وذلك إذا لم تنجح الجرعة القصوى للدواء الستاتيني في خفض مستويات الكولسترول بقدر كاف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وحده أو مع أدوية أخرى خافضة للكولسترول عندما لا تعمل الأدوية الستاتينية بشكل جيد أو إن لم يكن من الممكن استعمالها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت طفل يبلغ ۱٠&nbsp;أعوام أو أكثر وكان سبب ارتفاع مستوى الكولسترول في دمك هو حالة متوارثة في عائلتك (ارتفاع الكولسترول العائلي مختلف الأمشاج في الدم والمعروف اختصارا HeFH). يُعطى وحده أو مع علاجات أخرى خافضة للكولسترول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بالغا أو كنت طفلا يبلغ ۱٠&nbsp;أعوام أو أكثر وكان سبب ارتفاع مستوى الكولسترول في دمك هو حالة متوارثة في عائلتك (ارتفاع الكولسترول العائلي متماثل الأمشاج في الدم والمعروف اختصارا HoFH). ويتم إعطاؤه مع علاجات أخرى خافضة للكولسترول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت من البالغين وكان مستوى كولسترول دمك مرتفعا ومرض تصلب شرايين القلب والأوعية الدموية مثبتا لديك (سجل تعرّض لنوبة قلبية أو سكتة دماغية أو مشاكل في الأوعية الدموية). ويتم إعطاؤه:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع دواء ستاتيني أو دواء آخر من الأدوية الخافضة للكولسترول، وذلك إذا لم تنجح الجرعة القصوى للدواء الستاتيني في خفض مستويات الكولسترول بقدر كاف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وحده أو مع أدوية أخرى خافضة للكولسترول عندما لا تعمل الأدوية الستاتينية بشكل جيد أو إن لم يكن من الممكن استعمالها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;يستخدم ريباثا لدى المرضى الذين لا يتمكنون من السيطرة على مستويات الكولسترول لديهم بالاعتماد فقط على نظام غذائي خافض للكولسترول. ينبغي أن تستمر في اتباع النظام الغذائي الخافض للكولسترول أثناء تلقيك هذا الدواء. يمكن أن يساعد ريباثا على الوقاية من حدوث النوبة القلبية والسكتة الدماغية وبعض إجراءات القلب لاستعادة تدفق الدم إلى القلب الذي تباطأ بسبب تراكم ترسبات دهنية في شرايينك (تعرف أيضا بأمراض تصلب شرايين القلب والأوعية الدموية).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم ريباثا</strong> إذا كانت لديك حساسية (تحسس) تجاه إفولوكوماب أو أي من مكونات هذا الدواء الأخرى (مدرجة في القسم&nbsp;٦).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث مع طبيبك أو الصيدلي أو ممرضتك قبل أن تستعمل ريباثا إذا كان لديك أي مرض كبدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن غطاء الإبرة الخاص بالقلم الزجاجي المملوء مسبقا مصنوع من المطاط الطبيعي (وهو من مشتقات اللاتكس)، وهو ما قد يسبب تفاعلات تحسسية حادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من أجل تحسين إمكانية تتبع هذا الدواء، ينبغي لطبيبك أو الصيدلي تسجيل اسم المنتج الذي حصلت عليه ورقم الدفعة الخاص به في ملف المريض الخاص بك. قد ترغب كذلك في تسجيل هذه التفاصيل في حال طُلبت منك هذه المعلومات في المستقبل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">خضع استخدام ريباثا للدراسه في الأطفال الذين يبلغون ۱٠&nbsp;أعوام أو أكثر والذين يتلقون علاجا لارتفاع الكولسترول العائلي مختلف أو متماثل الأمشاج في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لم يخضع استخدام ريباثا لدى الأطفال الذين تقل أعمارهم عن ۱٠&nbsp;أعوام للدراسة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وريباثا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تستعمل حاليا، أو كنت قد استعملت مؤخرا، أو قد تستعمل لاحقا أية أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا كنت حاملا أو إذا كنت ترضعين رضاعة طبيعية أو إذا كنت تعتقدين أنك حامل أو إذا كنت تخططين للإنجاب، فاسألي طبيبك أو الصيدلي للحصول على النصيحة قبل تلقي هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لم يختبر ريباثا لدى النساء الحوامل. ومن غير المعروف ما إذا كان ريباثا قد يضر بالطفل في بطن أمه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المعروف ما إذا كان ريباثا يفرز في لبن الأم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم إخبار طبيبك إذا كنت ترضعين رضاعة طبيعية أو إذا كنت تنوين القيام بذلك. سيساعدك طبيبك في هذه الحالة في تقرير ما إذا كنت ستتوقفين عن الرضاعة الطبيعية أو عن استخدام ريباثا، وهذا من خلال المفاضلة ما بين مزايا الرضاعة الطبيعية بالنسبة للطفل وبين الفوائد التي تجنيها الأم من استخدام ريباثا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستعمال الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إن تأثير ريباثا على القدرة على القيادة وتشغيل الآلات ضئيل أو منعدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي ريباثا على الصوديوم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على أقل من ۱&nbsp;مليمول من الصوديوم (۲٣&nbsp;مجم) في كل جرعة، وهذا يعني أنه بالأساس &quot;خال من الصوديوم&quot;.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم هذا الدواء دوما بالشكل الذي أمرك به طبيبك تماما. راجع طبيبك إذا لم تكن متأكدا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعتمد الجرعة الموصى بها على الحالة الطبية الكامنة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة للبالغين المصابين بارتفاع الكولسترول الأولي في الدم وخلل في كمية الدهون المختلطة في الدم فإن الجرعة هي إما ۱٤٠&nbsp;مجم كل أسبوعين أو ٤۲٠&nbsp;مجم مرة واحدة كل شهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة إلى الأطفال الذين يبلغون ١٠&nbsp;أعوام أو أكثر المصابين بارتفاع الكولسترول العائلي مختلف الأمشاج في الدم فإن الجرعة هي إما ۱٤٠&nbsp;مجم كل أسبوعين أو ٤۲٠&nbsp;مجم مرة واحدة كل شهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة للبالغين أو الأطفال الذين يبلغون ١٠&nbsp;أعوام أو أكثر المصابين بارتفاع الكولسترول العائلي متماثل الأمشاج في الدم فإن الجرعة الموصى بها هي ٤۲٠&nbsp;مجم مرة واحدة كل شهر. وبعد ۱۲&nbsp;أسبوعا، قد يقرر طبيبك زيادة الجرعة إلى ٤۲٠&nbsp;مجم كل أسبوعين. إذا خضعت كذلك لإجراء الفِصادة، وهو يشبه غسيل الكلى تتم فيه إزالة الكولسترول والدهون الأخرى من الدم، قد يقرر طبيبك أن يبدأ بجرعة ٤۲٠&nbsp;مجم كل أسبوعين بحيث يتزامن موعدها مع علاج الفِصادة الذي تخضع له.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة للبالغين المصابين بمرض تصلب شرايين القلب والأوعية الدموية المثبت لديهم (سجل تعرّض لنوبة قلبية أو سكتة دماغية أو مشاكل في الأوعية الدموية) فإن الجرعة تكون إما ۱٤٠&nbsp;مجم كل أسبوعين أو ٤۲٠&nbsp;مجم مرة واحدة كل شهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعطى ريباثا كحقنة تحت الجلد (تحت الجلد).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا وصف طبيبك جرعة مقدارها ٤۲٠&nbsp;مجم، سيكون عليك استخدام ثلاث أقلام مملوءة مسبقا لأن كل قلم مملوء مسبقا لا يحتوي إلا على ۱٤٠&nbsp;مجم من الدواء. بعد وصول الحقن إلى درجة حرارة الغرفة، ينبغي إعطاء كل الحقن في غضون ٣٠&nbsp;دقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا قرر طبيبك أن بمقدورك أنت أو أحد الأشخاص الذين يعتنون بك إعطاء حقن ريباثا، فسيكون عليك أنت أو هذا الشخص أن تتلقيا تدريبا على كيفية تحضير هذه الحقن وإعطائها بشكل سليم. لا تحاول حَقن ريباثا حتى يقوم طبيبك أو ممرضتك بتعريفك على طريقة الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">انظر &quot;إرشادات الاستخدام &quot; المفصلة المعروضة في نهاية هذه النشرة للحصول على إرشادات بخصوص طريقة التخزين والتحضير وإعطاء حقن ريباثا في المنزل. في حالة استخدام القلم المملوء مسبقا، <strong>ضع الطرف (الأصفر) الصحيح للقلم على الجلد قبل الحقن.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل أن تبدأ بتلقي ريباثا، ينبغي أن تكون قد اتبعت نظاما غذائيا لتخفيض مستوى الكولسترول لديك. ينبغي أن تستمر في اتباع هذا النظام الغذائي الخافض للكولسترول أثناء تلقيك ريباثا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان طبيبك قد وصف لك ريباثا بالإضافة إلى دواء آخر خافض للكولسترول، فاتبع إرشادات طبيبك بخصوص طريقة استعمال هذه الأدوية معا. في هذه الحالة، الرجاء قراءة إرشادات الجرعة الواردة في النشرة الداخلية الخاصة بهذا الدواء والدواء الآخر أيضا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة الإفراط في استخدام ريباثا</strong></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">اتصل بطبيبك أو الصيدلي على الفور.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>في حالة نسيان استخدام ريباثا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">خذ ريباثا بأسرع ما يمكن من بعد تفويتك لجرعة منه. ثم اتصل بطبيبك وهو سيخبرك بالموعد الذي سيكون عليك تلقي جرعتك التالية فيه، ومن ثم، ستتبع الجدول الزمني الجديد تماما كما أمرك به طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كافة الأدوية، يمكن لهذا الدواء أن يسبب آثارا جانبية، رغم أنها قد لا تصيب كافة المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة (قد تؤثر إلى حدود&nbsp;١ عن كل ١٠&nbsp;أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنفلونزا (ارتفاع درجة الحرارة، التهاب الحلق، سيلان الأنف، السعال والقشعريرة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزلة برد، على سبيل المثال سيلان الأنف، التهاب الحلق أو عدوى الجيوب الأنفية (التهاب البلعوم الأنفي أو عدوى الجهاز التنفسي العلوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالمرض (الغثيان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الظهر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل (ألم مفصلي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ألم العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات في موضع الحقن، مثل الكدمات أو الاحمرار أو النزيف أو الألم أو التورم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تحسسية بما في ذلك الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الصداع</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة (قد تؤثر إلى حدود&nbsp;١ عن كل ١٠٠&nbsp;شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرى، تحاديب حمراء حاكة على جلدك (أرتيكاريا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض شبيهة بالإنفلونزا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة (قد تؤثر إلى حدود&nbsp;١ عن كل ١٠٠٠&nbsp;شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه أو الفم أو اللسان أو الحلق (وذمة وعائية)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تعرضت لأي آثار جانبية، يرجى إبلاغ طبيبك أو الصيدلي أو الممرض(ة). ويشمل ذلك أي آثار جانبية غير مدرجة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية، يمكنك أن تساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد انقضاء تاريخ انتهاء الصلاحية المدون على البطاقة المثبتة وعلى العبوة بعد كلمة EXP&rlm;. ويشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحفظ الدواء في الثلاجة (٢&deg;م&nbsp;‑&nbsp;٨&deg;م)، ولا يجب تجميده.</p><p dir="RTL">يحفظ داخل العبوة الأصلية لحمايته من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجوز ترك قلمك المملوء مسبقا خارج الثلاجة حتى يصل إلى درجة حرارة الغرفة (حتى ۲٥&deg;م) قبل الحقن. سيجعل ذلك عملية الحقن أكثر راحة بالنسبة لك. بعد إخراج ريباثا من الثلاجة، يمكن تخزينه في درجة حرارة الغرفة (حتى ۲٥&deg;م) داخل العبوة الأصلية ، مع العلم بأنه من الضروري استعماله في غضون شهر واحد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدواء إذا لاحظت وجود تغير في اللون أو كتل أو رقائق كبيرة أو جسيمات ملونة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينبغي التخلص من الأدوية عن طريق مياه الصرف أو نفايات المنزل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستعملها. فهذه الإجراءات من شأنها الحفاظ على البيئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>عما يحتوي ريباثا</strong></p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المادة الفعالة هي إفولوكوماب. يحتوي كل قلم مملوء مسبقا على ۱٤٠&nbsp;مجم إفولوكوماب في ۱&nbsp;مليلتر من المحلول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: البرولين) ٢٥ مجم)، حمض الخليك الجليدي) ١٫٢ مجم(، بولي سوربات ٨٠ (٠٫١٠ مجم(، هيدروكسيد الصودیوم وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل ريباثا وماهي محتويات العبوة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">ريباثا هو عبارة عن محلول من صاف إلى غميم، ومن عديم اللون إلى مائل للصفرة، وهو عمليا خال من الجسيمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل عبوة على قلم واحد، قلمين، ثلاث أقلام أو ستة أقلام مملوءة مسبقا للاستخدام مرة واحدة.</p><p dir="RTL">قد لا تتوفر جميع أحجام العبوات في الأسواق.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موقع تصنيع المُنتج الدوائي</strong></p><p dir="RTL">Amgen Manufacturing Limited</p><p dir="RTL">State Road 31</p><p dir="RTL">Kilometer 24.6</p><p dir="RTL">Juncos 00777-4060</p><p dir="RTL">Puerto Rico</p><p dir="RTL">الولايات المتحدة الأمريكية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>صاحب ترخيص التسويق والجهة المصنعة:</strong></p><p dir="RTL">‪Amgen Europe B.V.</p><p dir="RTL">Minervum 7061</p><p dir="RTL">4817&nbsp;ZK Breda</p><p dir="RTL">هولندا</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم اعتماد هذه النشرة بتاريخ أبريل ٢٠٢٢.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Repatha 140 mg solution for injection in pre-filled pen
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each pre-filled pen contains 140 mg of evolocumab in 1 mL of solution. 

Repatha is a human IgG2 monoclonal antibody produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection) in pre-filled pen (SureClick).

The solution is clear to opalescent, colourless to yellowish, and practically free from particles.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypercholesterolaemia and mixed dyslipidaemia</u></p><p><u>&nbsp;</u></p><p>Repatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non‑familial) or mixed dyslipidaemia, and in paediatric patients aged 10 years and over with heterozygous familial hypercholesterolaemia, as an adjunct to diet:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL‑C goals with the maximum tolerated dose of a statin or,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.</p><p>&nbsp;</p><p><u>Homozygous familial hypercholesterolaemia</u></p><p><u>&nbsp;</u></p><p>Repatha is indicated in adults and paediatric patients aged 10 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.</p><p>&nbsp;</p><p><u>Established atherosclerotic cardiovascular disease</u></p><p><u>&nbsp;</u></p><p>Repatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with the maximum tolerated dose of a statin with or without other lipid‑lowering therapies or,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.</p><p>&nbsp;</p><p>For study results with respect to effects on LDL-C, cardiovascular events and populations studied, see section 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prior to initiating evolocumab, secondary causes of hyperlipidaemia or mixed dyslipidaemia (e.g.,&nbsp;nephrotic syndrome, hypothyroidism) should be excluded.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>Primary hypercholesterolaemia and mixed dyslipidaemia (including heterozygous familial hypercholesterolaemia)</p><p>&nbsp;</p><p>Adults and paediatric patients (aged 10 years and over)</p><p>The recommended dose of evolocumab is either 140&nbsp;mg every two weeks or 420&nbsp;mg once monthly; both doses are clinically equivalent.</p><p>&nbsp;</p><p>Homozygous familial hypercholesterolaemia in adults and paediatric patients aged 10 years and over</p><p>The initial recommended dose is 420&nbsp;mg once monthly. After 12 weeks of treatment, dose frequency can be up‑titrated to 420&nbsp;mg once every 2 weeks if a clinically meaningful response is not achieved. Patients on apheresis may initiate treatment with 420&nbsp;mg every two weeks to correspond with their apheresis schedule.</p><p>&nbsp;</p><p><em>Established atherosclerotic cardiovascular disease </em><em>in adults</em></p><p>The recommended dose of evolocumab is either 140&nbsp;mg every two weeks or 420&nbsp;mg once monthly; both doses are clinically equivalent.</p><p>&nbsp;</p><p>Special populations</p><p>&nbsp;</p><p><em>Elderly patients (age &ge; 65 years)</em></p><p>No dose adjustment is necessary in elderly patients.</p><p>&nbsp;</p><p><em>Patients with renal impairment</em></p><p>No dose adjustment is necessary in patients with renal impairment (see section 5.2).</p><p><strong><em>&nbsp;</em></strong></p><p><em>Patients with hepatic impairment</em></p><p>No dose adjustment is necessary in patients with mild hepatic impairment, see section&nbsp;4.4 for patients with moderate and severe hepatic impairment.</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>The safety and effectiveness of Repatha have not been established in paediatric patients with heterozygous familial hypercholesterolaemia (HeFH) or homozygous familial hypercholesterolaemia (HoFH) who are younger than 10&nbsp;years old or in paediatric patients with other types of hyperlipidaemia.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Subcutaneous use.</p><p>&nbsp;</p><p>Evolocumab is for subcutaneous injection into the abdomen, thigh or upper arm region. Injection sites should be rotated and injections should not be given into areas where the skin is tender, bruised, red, or hard.</p><p>&nbsp;</p><p>Evolocumab must not be administered intravenously or intramuscularly.</p><p>&nbsp;</p><p>The 140&nbsp;mg dose should be delivered using a single pre-filled pen. The 420&nbsp;mg dose should be delivered using three pre-filled pens administered consecutively within 30 minutes.</p><p>Repatha is intended for patient self-administration after proper training. Administration of evolocumab can also be performed by an individual who has been trained to administer the product.</p><p>&nbsp;</p><p>For single use only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Traceability</p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>In patients with moderate hepatic impairment, a reduction in total evolocumab exposure was observed that may lead to a reduced effect on LDL‑C reduction. Therefore, close monitoring may be warranted in these patients.</p><p>&nbsp;</p><p>Patients with severe hepatic impairment (Child-Pugh class C) have not been studied (see section 5.2). Evolocumab should be used with caution in patients with severe hepatic impairment.</p><p>&nbsp;</p><p><u>Dry natural rubber</u></p><p>&nbsp;</p><p>The needle cover of the pre-filled pen is made from dry natural rubber (a derivative of latex), which may cause severe allergic reactions.</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.</p><p>&nbsp;</p><p>The pharmacokinetic interaction between statins and evolocumab was evaluated in the clinical trials. An approximately 20% increase in the clearance of evolocumab was observed in patients co-administered statins. This increased clearance is in part mediated by statins increasing the concentration of Proprotein Convertase Subtilisin/Kexin Type&nbsp;9 (PCSK9) which did not adversely impact the pharmacodynamic effect of evolocumab on lipids. No statin dose adjustments are necessary when used in combination with evolocumab.</p><p>&nbsp;</p><p>No studies on pharmacokinetic and pharmacodynamics interaction between evolocumab and lipid‑lowering medicinal products other than statins and ezetimibe have been conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>&nbsp;</em></strong></p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no or limited amount of data from the use of Repatha in pregnant women.</p><p><u>&nbsp;</u></p><p>Animal studies do not indicate direct or indirect effects with respect to reproductive toxicity (see section&nbsp;5.3).</p><p>&nbsp;</p><p>Repatha should not be used during pregnancy unless the clinical condition of the woman requires treatment with evolocumab.</p><p><u>&nbsp;</u></p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether evolocumab is excreted in human milk.</p><p>&nbsp;</p><p>A risk to breastfed newborns/infants cannot be excluded.</p><p>&nbsp;</p><p>A decision must be made whether to discontinue breast-feeding or discontinue/abstain from Repatha therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p><em>&nbsp;</em></p><p>No data on the effect of evolocumab on human fertility are available. Animal studies did not show any effects on fertility endpoints at area under the concentration time curve (AUC) exposure levels much higher than in patients receiving evolocumab at 420&nbsp;mg once monthly (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repatha has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p>The most commonly reported adverse reactions at the recommended doses are nasopharyngitis (7.4%), upper respiratory tract infection (4.6%), back pain (4.4%), arthralgia (3.9%), influenza (3.2%), and injection site reactions (2.2%). The safety profile in the homozygous familial hypercholesterolaemia population was consistent with that demonstrated in the primary hypercholesterolaemia and mixed dyslipidaemia population.</p><p><strong>&nbsp;</strong></p><p><u>Tabulated list of adverse reactions</u></p><p><strong><em>&nbsp;</em></strong></p><p>Adverse reactions reported in pivotal, controlled clinical studies, and spontaneous reporting, are displayed by system organ class and frequency in table 1 below using the following convention: very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000) and very rare (&lt;&nbsp;1/10,000).</p><p><strong>&nbsp;</strong></p><p><strong>Table 1. Adverse reactions </strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ class (SOC)</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Influenza</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nasopharyngitis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Angioedema</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Injection site reactions<sup>1</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Influenza-like illness</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></tbody></table><p><sup>1 </sup>See section Description of selected adverse reactions.</p><p>&nbsp;</p><p>The safety profile was consistent between subjects with post-baseline LDL-C&nbsp;&lt;&nbsp;25&nbsp;mg/dL (0.65&nbsp;mmol/L) or &lt;&nbsp;40&nbsp;mg/dL (1.03&nbsp;mmol/L) compared to subjects with higher post-baseline LDL-C (&ge;&nbsp;40&nbsp;mg/dL[1.03&nbsp;mmol/L]), with median (Q1, Q3) Repatha exposure of 84.2 (78.1, 89.8) months in subjects who continued on Repatha and 59.8 (52.8, 60.3) months in subjects on placebo who switched to Repatha in an open-label extension study.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Injection site reactions</em></p><p>The most frequent injection site reactions were injection site bruising, erythema, haemorrhage, injection site pain and swelling.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The safety and effectiveness of Repatha have been established in paediatric patients with heterozygous and homozygous familial hypercholesterolaemia. A clinical study to evaluate the effects of Repatha was conducted in 158&nbsp;paediatric patients aged &ge;&nbsp;10 to &lt;&nbsp;18&nbsp;years old with heterozygous familial hypercholesterolaemia. No new safety concerns were identified and the safety data in this paediatric population was consistent with the known safety profile of the product in adults with heterozygous familial hypercholesterolaemia. Twenty-six paediatric patients with homozygous familial hypercholesterolaemia have been treated with Repatha in clinical studies conducted in patients aged &ge;&nbsp;10 to &lt;&nbsp;18&nbsp;years. No difference in safety was observed between paediatric and adult patients with homozygous familial hypercholesterolaemia.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Elderly population</u></p><p>&nbsp;</p><p>Of the 18,546 patients treated with evolocumab in double-blind clinical studies 7,656&nbsp;(41.3%) were &ge;&nbsp;65 years old, while 1,500 (8.1%) were &ge;&nbsp;75 years old. No overall differences in safety or efficacy were observed between these patients and younger patients.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p><u>&nbsp;</u></p><p>In clinical studies, 0.3% of patients (48 out of 17,992 patients) treated with at least one dose of evolocumab tested positive for binding antibody development. The patients whose sera tested positive for binding antibodies were further evaluated for neutralising antibodies and none of the patients tested positive for neutralising antibodies. The presence of anti-evolocumab binding antibodies did not impact the pharmacokinetic profile, clinical response, or safety of evolocumab.</p><p>&nbsp;</p><p>The development of anti-evolocumab antibodies was not detected in clinical trials of paediatric patients treated with Repatha.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to their local representative.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>To report any side effects:&nbsp;</p><p>Saudi Arabia:&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):&nbsp;&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax : +966-11-205-7662&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No adverse effects were observed in animal studies at exposures up to 300-fold higher than those in patients treated with 420&nbsp;mg evolocumab once monthly.</p><p>&nbsp;</p><p>There is no specific treatment for evolocumab overdose. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: lipid modifying agents, other lipid modifying agents. ATC code: C10AX13</p><p><em>&nbsp;</em></p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Evolocumab binds selectively to PCSK9 and prevents circulating PCSK9 from binding to the low density lipoprotein receptor (LDLR) on the liver cell surface, thus preventing PCSK9-mediated LDLR degradation. Increasing liver LDLR levels results in associated reductions in serum LDL-cholesterol (LDL-C).</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><s>&nbsp;</s></p><p>In clinical trials, evolocumab reduced unbound PCSK9, LDL-C, TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1, VLDL-C, TG and Lp(a), and increased HDL-C and ApoA1 in patients with primary hypercholesterolaemia and mixed dyslipidaemia.</p><p>&nbsp;</p><p>A single subcutaneous administration of 140&nbsp;mg or 420&nbsp;mg evolocumab resulted in maximum suppression of circulating unbound PCSK9 by 4 hours followed by a reduction in LDL-C reaching a mean nadir in response by 14 and 21 days, respectively. Changes in unbound PCSK9 and serum lipoproteins were reversible upon discontinuation of evolocumab. No increase in unbound PCSK9 or LDL-C above baseline was observed during the washout of evolocumab suggesting that compensatory mechanisms to increase production of PCSK9 and LDL-C do not occur during treatment.</p><p>&nbsp;</p><p>Subcutaneous regimens of 140&nbsp;mg every 2 weeks and 420&nbsp;mg once monthly were equivalent in average LDL-C lowering (mean of weeks 10 and 12) resulting in -72% to -57% from baseline compared with placebo. Treatment with evolocumab resulted in a similar reduction of LDL-C when used alone or in combination with other lipid-lowering therapies.</p><p>&nbsp;</p><p><u>Clinical efficacy in primary hypercholesterolaemia and mixed dyslipidaemia</u></p><p>&nbsp;</p><p>LDL-C reduction of approximately 55% to 75% was achieved with evolocumab as early as week 1 and maintained during long-term therapy. Maximal response was generally achieved within 1 to 2 weeks after dosing with 140&nbsp;mg every 2 weeks and 420&nbsp;mg once monthly. Evolocumab was effective in all subgroups relative to placebo and ezetimibe, with no notable differences observed between subgroups, such as age, race, gender, region, body-mass index, National Cholesterol Education Program risk, current smoking status, baseline coronary heart disease (CHD) risk factors, family history of premature CHD, glucose tolerance status, (i.e. diabetes mellitus type 2, metabolic syndrome, or neither), hypertension, statin dose and intensity, unbound baseline PCSK9, baseline LDL-C and baseline TG.</p><p><u>&nbsp;</u></p><p>In 80-85% of all primary hyperlipidaemia patients treated with either dose, evolocumab demonstrated a &ge;&nbsp;50% reduction in LDL-C at the mean of weeks 10 and 12. Up to 99% of patients treated with either dose of evolocumab achieved an LDL-C of &lt;&nbsp;2.6&nbsp;mmol/L and up to 95% achieved an LDL-C &lt;&nbsp;1.8&nbsp;mmol/L at the mean of weeks 10 and 12.</p><p>&nbsp;</p><p><u>Combination with a statin and statin with other lipid-lowering therapies</u></p><p>&nbsp;</p><p>LAPLACE-2 was an international, multicentre, double-blind, randomised, 12-week study in 1,896 patients with primary hypercholesterolaemia or mixed dyslipidaemia who were randomised to receive evolocumab in combination with statins (rosuvastatin, simvastatin or atorvastatin). Evolocumab was compared to placebo for the rosuvastatin and simvastatin groups and compared with placebo and ezetimibe for the atorvastatin group.</p><p>&nbsp;</p><p>Repatha significantly reduced LDL-C from baseline to mean of weeks 10 and 12 compared with placebo for the rosuvastatin and simvastatin groups and compared with placebo and ezetimibe for the atorvastatin group (p&nbsp;&lt;&nbsp;0.001). Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1, VLDL-C, TG and Lp(a) and increased HDL-C from baseline to mean of weeks 10 and 12 as compared to placebo for the rosuvastatin and simvastatin groups (p&nbsp;&lt;&nbsp;0.05) and significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1 and Lp(a), compared with placebo and ezetimibe for the atorvastatin group (p&nbsp;&lt;&nbsp;0.001) (see tables 2 and 3).</p><p>&nbsp;</p><p>RUTHERFORD-2 was an international, multicentre, double-blind, randomised, placebo-controlled, 12-week study in 329 patients with heterozygous familial hypercholesterolaemia on lipid-lowering therapies. Repatha significantly reduced LDL-C from baseline to mean of weeks 10 and 12 compared with placebo (p&nbsp;&lt;&nbsp;0.001). Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1, VLDL-C, TG and Lp(a) and increased HDL-C and ApoA1 from baseline to mean of weeks 10 and 12 compared to placebo (p&nbsp;&lt;&nbsp;0.05) (see table 2).</p><p><u>&nbsp;</u></p><p><strong>Table 2. Treatment effects of evolocumab compared with placebo in patients with primary hypercholesterolaemia and mixed dyslipidaemia - mean percent change from baseline to average of weeks 10 and 12 (%, 95% CI)</strong></p><p><u>&nbsp;</u></p><table border="0" cellspacing="0" cellpadding="0" style="width:104%"><tbody><tr><td style="vertical-align:top"><p><strong>Study</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>LDL-C</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Non-HDL-C</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>ApoB</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>TC</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Lp(a)</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>VLDL-C</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>HDL-C</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>TG</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>ApoA1</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>TC/</strong></p><p><strong>HDL-C ratio</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>ApoB/</strong></p><p><strong>ApoA1 ratio</strong></p><p><strong>%</strong></p></td></tr><tr><td rowspan="2"><p>LAPLACE-2</p><p>(HMD)</p><p>(combined rosuvastatin, simvastatin, &amp; atorvastatin groups)</p></td><td><p>140&nbsp;mg Q2W (N&nbsp;=&nbsp;555)</p></td><td><p>-72<sup>b</sup></p><p>(‑75, ‑69)</p></td><td><p>-60<sup>b</sup></p><p>(‑63, ‑58)</p></td><td><p>-56<sup>b</sup></p><p>(‑58, ‑53)</p></td><td><p>-41<sup>b</sup></p><p>(‑43, ‑39)</p></td><td><p>-30<sup>b</sup></p><p>(‑35, ‑25)</p></td><td><p>-18<sup>b</sup></p><p>(‑23, ‑14)</p></td><td><p>6<sup>b</sup></p><p>(4, 8)</p></td><td><p>-17<sup>b</sup></p><p>(‑22, ‑13)</p></td><td><p>3<sup>b</sup></p><p>(1, 5)</p></td><td><p>-45<sup>b</sup></p><p>(‑47, ‑42)</p></td><td><p>-56<sup>b</sup></p><p>(‑59, ‑53)</p></td></tr><tr><td><p>420&nbsp;mg QM (N&nbsp;=&nbsp;562)</p></td><td><p>-69<sup>b</sup></p><p>(‑73, ‑65)</p></td><td><p>-60<sup>b</sup></p><p>(‑63, ‑57)</p></td><td><p>-56<sup>b</sup></p><p>(‑58, ‑53)</p></td><td><p>-40<sup>b</sup></p><p>(‑42, ‑37)</p></td><td><p>-27<sup>b</sup></p><p>(‑31, ‑24)</p></td><td><p>-22<sup>b</sup></p><p>(‑28, ‑17)</p></td><td><p>8<sup>b</sup></p><p>(6, 10)</p></td><td><p>-23<sup>b</sup></p><p>(‑28, ‑17)</p></td><td><p>5<sup>b</sup></p><p>(3, 7)</p></td><td><p>-46<sup>b</sup></p><p>(‑48, ‑43)</p></td><td><p>-58<sup>b</sup></p><p>(‑60, ‑55)</p></td></tr><tr><td rowspan="2"><p>RUTHERFORD-2</p><p>(HeFH)</p></td><td><p>140&nbsp;mg Q2W (N&nbsp;=&nbsp;110)</p></td><td><p>-61<sup>b</sup></p><p>(‑67, ‑55)</p></td><td><p>-56<sup>b</sup></p><p>(‑61, ‑51)</p></td><td><p>-49<sup>b</sup></p><p>(‑54, ‑44)</p></td><td><p>-42<sup>b</sup></p><p>(‑46, ‑38)</p></td><td><p>-31<sup>b</sup></p><p>(‑38, ‑24)</p></td><td><p>-22<sup>b</sup></p><p>(‑29, ‑16)</p></td><td><p>8<sup>b</sup></p><p>(4, 12)</p></td><td><p>-22<sup>b</sup></p><p>(‑29, ‑15)</p></td><td><p>7<sup>a</sup></p><p>(3, 12)</p></td><td><p>-47<sup>b</sup></p><p>(‑51, ‑42)</p></td><td><p>-53</p><p>(‑58, ‑48)</p></td></tr><tr><td><p>420&nbsp;mg QM (N&nbsp;=&nbsp;110)</p></td><td><p>-66<sup>b</sup></p><p>(‑72, ‑61)</p></td><td><p>-60<sup>b</sup></p><p>(‑65, ‑55)</p></td><td><p>-55<sup>b</sup></p><p>(‑60, ‑50)</p></td><td><p>-44<sup>b</sup></p><p>(‑48, ‑40)</p></td><td><p>-31<sup>b</sup></p><p>(‑38, ‑24)</p></td><td><p>-16<sup>b</sup></p><p>(‑23, ‑8)</p></td><td><p>9<sup>b</sup></p><p>(5, 14)</p></td><td><p>-17<sup>b</sup></p><p>(‑24, ‑9)</p></td><td><p>5<sup>a</sup></p><p>(1, 9)</p></td><td><p>-49<sup>b</sup></p><p>(‑54, ‑44)</p></td><td><p>-56<sup>b</sup></p><p>(‑61, ‑50)</p></td></tr></tbody></table><p>Key: Q2W = once every 2 weeks, QM = once monthly, HMD = Primary hypercholesterolaemia and mixed dyslipidaemia, HeFH = Heterozygous familial hypercholesterolaemia, <sup>a</sup> p value &lt;&nbsp;0.05 when compared with placebo, <sup>b</sup>&nbsp;p value &lt;&nbsp;0.001 when compared with placebo.</p><p><u>&nbsp;</u></p><p><u>Statin-intolerant patients</u></p><p>&nbsp;</p><p>GAUSS-2 was an international, multicentre, double-blind, randomised, ezetimibe-controlled, 12-week study in 307 patients who were statin-intolerant or unable to tolerate an effective dose of a statin. Repatha significantly reduced LDL-C compared with ezetimibe (p&nbsp;&lt;&nbsp;0.001). Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1 and Lp(a), from baseline to mean of weeks 10 and 12 compared to ezetimibe (p&nbsp;&lt;&nbsp;0.001) (see table 3).</p><p>&nbsp;</p><p><u>Treatment in the absence of a statin</u></p><p>&nbsp;</p><p>MENDEL-2 was an international, multicentre, double-blind, randomised, placebo and ezetimibe‑controlled, 12-week study of Repatha in 614 patients with primary hypercholesterolaemia and mixed dyslipidaemia. Repatha significantly reduced LDL-C from baseline to mean of weeks 10 and 12 compared with both placebo and ezetimibe (p&nbsp;&lt;&nbsp;0.001). Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1 and Lp(a), from baseline to mean of weeks 10 and 12 compared with both placebo and ezetimibe (p&nbsp;&lt;&nbsp;0.001) (see table 3).</p><p>&nbsp;</p><p><strong>Table 3. Treatment effects of evolocumab compared with ezetimibe in patients with primary hypercholesterolaemia and mixed dyslipidaemia - mean percent change from baseline to average of weeks 10 and 12 (%, 95% CI)</strong></p><p><u>&nbsp;</u></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Study</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>LDL-C</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Non-HDL-C</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>ApoB</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>TC</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Lp(a)</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>VLDL-C</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>HDL-C</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>TG</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>ApoA1</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>TC/</strong></p><p><strong>HDL-C ratio</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>ApoB/</strong></p><p><strong>ApoA1 ratio</strong></p><p><strong>%</strong></p></td></tr><tr><td rowspan="2"><p>LAPLACE-2</p><p>(HMD)</p><p>(combined atorvastatin groups)</p></td><td><p>140&nbsp;mg Q2W (N&nbsp;=&nbsp;219)</p></td><td><p>-43<sup>c</sup></p><p>(‑50, ‑37)</p></td><td><p>-34<sup>c</sup></p><p>(‑39, ‑30)</p></td><td><p>-34<sup>c</sup></p><p>(‑38, ‑30)</p></td><td><p>-23<sup>c</sup></p><p>(‑26, ‑19)</p></td><td><p>-30<sup>c</sup></p><p>(‑35, ‑25)</p></td><td><p>-1</p><p>(‑7, 5)</p></td><td><p>7<sup>c</sup></p><p>(4, 10)</p></td><td><p>-2</p><p>(‑9, 5)</p></td><td><p>7<sup>c</sup></p><p>(4, 9)</p></td><td><p>-27<sup>c</sup></p><p>(‑30, ‑23)</p></td><td><p>-38<sup>c</sup></p><p>(‑42, ‑34)</p></td></tr><tr><td><p>420&nbsp;mg QM (N&nbsp;=&nbsp;220)</p></td><td><p>-46<sup>c</sup></p><p>(‑51, ‑40)</p></td><td><p>-39<sup>c</sup></p><p>(‑43, ‑34)</p></td><td><p>-40<sup>c</sup></p><p>(‑44, ‑36)</p></td><td><p>-25<sup>c</sup></p><p>(‑29, ‑22)</p></td><td><p>-33<sup>c</sup></p><p>(‑41, ‑26)</p></td><td><p>-7<sup> </sup></p><p>(‑20, 6)</p></td><td><p>8<sup>c</sup></p><p>(5, 12)</p></td><td><p>-8</p><p>(‑21, 5)</p></td><td><p>7<sup>c</sup></p><p>(2, 11)</p></td><td><p>-30<sup>c</sup></p><p>(‑34, ‑26)</p></td><td><p>-42<sup>c</sup></p><p>(‑47, ‑38)</p></td></tr><tr><td rowspan="2"><p>GAUSS-2</p><p>(statin‑intolerant)</p></td><td><p>140&nbsp;mg Q2W (N&nbsp;=&nbsp;103)</p></td><td><p>-38<sup>b</sup></p><p>(‑44, ‑33)</p></td><td><p>-32<sup>b</sup></p><p>(‑36, ‑27)</p></td><td><p>-32<sup>b</sup></p><p>(‑37, ‑27)</p></td><td><p>-24<sup>b</sup></p><p>(‑28, ‑20)</p></td><td><p>-24<sup>b</sup></p><p>(‑31, ‑17)</p></td><td><p>-2</p><p>(‑10, 7)</p></td><td><p>5</p><p>(1, 10)</p></td><td><p>-3</p><p>(‑11, 6)</p></td><td><p>5<sup>a</sup></p><p>(2, 9)</p></td><td><p>-27<sup>b</sup></p><p>(‑32, ‑23)</p></td><td><p>-35<sup>b</sup></p><p>(‑40, ‑30)</p></td></tr><tr><td><p>420&nbsp;mg QM (N&nbsp;=&nbsp;102)</p></td><td><p>-39<sup>b</sup></p><p>(‑44, ‑35)</p></td><td><p>-35<sup>b</sup></p><p>(‑39, ‑31)</p></td><td><p>-35<sup>b</sup></p><p>(‑40, ‑30)</p></td><td><p>-26<sup>b</sup></p><p>(‑30, ‑23)</p></td><td><p>-25<sup>b</sup></p><p>(‑34, ‑17)</p></td><td><p>-4</p><p>(‑13, 6)</p></td><td><p>6</p><p>(1, 10)</p></td><td><p>-6</p><p>(‑17, 4)</p></td><td><p>3</p><p>(‑1, 7)</p></td><td><p>-30<sup>b</sup></p><p>(‑35, ‑25)</p></td><td><p>-36<sup>b</sup></p><p>(‑42, ‑31)</p></td></tr><tr><td rowspan="2"><p>MENDEL-2 (treatment in the absence of a statin)</p></td><td><p>140&nbsp;mg Q2W</p><p>(N&nbsp;=&nbsp;153)</p></td><td><p>-40<sup>b</sup></p><p>(‑44, ‑37)</p></td><td><p>-36<sup>b</sup></p><p>(‑39, ‑32)</p></td><td><p>-34<sup>b</sup></p><p>(‑37, ‑30)</p></td><td><p>-25<sup>b</sup></p><p>(‑28, ‑22)</p></td><td><p>-22<sup>b</sup></p><p>(‑29, ‑16)</p></td><td><p>-7</p><p>(‑14, 1)</p></td><td><p>6<sup>a</sup></p><p>(3, 9)</p></td><td><p>-9</p><p>(‑16, ‑1)</p></td><td><p>3</p><p>(0, 6)</p></td><td><p>-29<sup>b</sup></p><p>(‑32, ‑26)</p></td><td><p>-35<sup>b</sup></p><p>(‑39, ‑31)</p></td></tr><tr><td><p>420&nbsp;mg QM</p><p>(N&nbsp;=&nbsp;153)</p></td><td><p>-41<sup>b</sup></p><p>(‑44, ‑37)</p></td><td><p>-35<sup>b</sup></p><p>(‑38, ‑33)</p></td><td><p>-35<sup>b</sup></p><p>(‑38, ‑31)</p></td><td><p>-25<sup>b</sup></p><p>(‑28, ‑23)</p></td><td><p>-20<sup>b</sup></p><p>(‑27, ‑13)</p></td><td><p>-10</p><p>(‑19, ‑1)</p></td><td><p>4</p><p>(1, 7)</p></td><td><p>-9</p><p>(‑18, 0)</p></td><td><p>4<sup>a</sup></p><p>(1, 7)</p></td><td><p>-28<sup>b</sup></p><p>(‑31, ‑24)</p></td><td><p>-37<sup>b</sup></p><p>(‑41, ‑32)</p></td></tr></tbody></table><p>Key: Q2W = once every 2 weeks, QM = once monthly, HMD = Primary hypercholesterolaemia and mixed dyslipidaemia, <sup>a</sup> p value &lt;&nbsp;0.05 when compared with ezetimibe, <sup>b</sup> p value &lt;&nbsp;0.001 when compared with ezetimibe, <sup>c </sup>nominal&nbsp;p&nbsp;value&nbsp;&lt;&nbsp;0.001 when compared with ezetimibe.</p><p><u>&nbsp;</u></p><p><u>Long-term efficacy in primary hypercholesterolaemia and mixed dyslipidaemia</u></p><p><u>&nbsp;</u></p><p>DESCARTES was an international, multicentre, double-blind, randomised, placebo-controlled, 52‑week study in 901 patients with hyperlipidaemia who received diet alone, atorvastatin, or a combination of atorvastatin and ezetimibe. Repatha 420&nbsp;mg once monthly significantly reduced LDL‑C from baseline at 52&nbsp;weeks compared with placebo (p&nbsp;&lt;&nbsp;0.001). Treatment effects were sustained over 1 year as demonstrated by reduction in LDL-C from week 12 to week 52. Reduction in LDL-C from baseline at week 52 compared with placebo was consistent across background lipid‑lowering therapies optimised for LDL-C and cardiovascular risk.</p><p>&nbsp;</p><p>Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1, VLDL-C, TG and Lp(a), and increased HDL-C and ApoA1 at week 52 compared with placebo (p&nbsp;&lt;&nbsp;0.001) (see table&nbsp;4).</p><p>&nbsp;</p><p><strong>Table 4. Treatment effects of evolocumab compared with placebo in patients with primary hypercholesterolaemia and mixed dyslipidaemia - mean percent change from baseline to week 52 (%, 95% CI)</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:101%"><tbody><tr><td style="vertical-align:top"><p><strong>Study</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>LDL-C</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Non-HDL-C</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>ApoB</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>TC</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Lp(a)</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>VLDL-C</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>HDL-C</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>TG</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>ApoA1</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>TC/</strong></p><p><strong>HDL-C ratio</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>ApoB/</strong></p><p><strong>ApoA1 ratio</strong></p><p><strong>%</strong></p></td></tr><tr><td><p>DESCARTES</p></td><td style="vertical-align:top"><p>420&nbsp;mg</p><p>QM</p><p>(N&nbsp;=&nbsp;599)</p></td><td><p>-59<sup>b</sup></p><p>(‑64, ‑55)</p></td><td><p>-50<sup>b</sup></p><p>(‑54, ‑46)</p></td><td><p>-44<sup>b</sup></p><p>(‑48, ‑41)</p></td><td><p>-33<sup>b</sup></p><p>(‑36, ‑31)</p></td><td><p>-22<sup>b</sup></p><p>(‑26, ‑19)</p></td><td><p>-29<sup>b</sup></p><p>(‑40, ‑18)</p></td><td><p>5<sup>b</sup></p><p>(3, 8)</p></td><td><p>-12<sup>b</sup></p><p>(‑17, ‑6)</p></td><td><p>3<sup>a</sup></p><p>(1, 5)</p></td><td><p>-37<sup>b</sup></p><p>(‑40, ‑34)</p></td><td><p>-46<sup>b</sup></p><p>(‑50, ‑43)</p></td></tr><tr><td colspan="13" style="vertical-align:top"><p>Key: QM = once monthly, <sup>a </sup>nominal p value &lt;&nbsp;0.001 when compared with placebo, <sup>b </sup>p value &lt;&nbsp;0.001 when compared with placebo.</p></td></tr></tbody></table><p>&nbsp;</p><p>OSLER and OSLER-2 were two randomised, controlled, open-label extension studies to assess the long-term safety and efficacy of Repatha in patients who completed treatment in a &lsquo;parent&rsquo; study. In each extension study, patients were randomised 2:1 to receive either Repatha plus standard of care (evolocumab group) or standard of care alone (control group) for the first year of the study. At the end of the first year (week 52 in OSLER and week 48 in OSLER-2), patients entered the all Repatha period in which all patients received open-label Repatha for either another 4 years (OSLER) or 2&nbsp;years (OSLER‑2).</p><p>&nbsp;</p><p>A total of 1,324 patients enrolled in OSLER. Repatha 420&nbsp;mg once monthly significantly reduced LDL-C from baseline at week 12 and week 52 compared with control (nominal p&nbsp;&lt;&nbsp;0.001). Treatment effects were maintained over 272 weeks as demonstrated by reduction in LDL-C from week 12 in the parent study to week 260 in the open-label extension. A total of 3,681 patients enrolled in OSLER-2. Repatha significantly reduced LDL-C from baseline at week 12 and week&nbsp;48 compared with control (nominal p&nbsp;&lt;&nbsp;0.001). Treatment effects were maintained as demonstrated by reduction in LDL-C from week 12&nbsp;to week 104 in the open-label extension. Repatha significantly reduced TC, ApoB, non‑HDL-C, TC/HDL-C, ApoB/ApoA1, VLDL-C, TG and Lp(a), and increased HDL-C and ApoA1 from baseline to week 52 in OSLER and to week 48 in OSLER-2 compared with control (nominal p&nbsp;&lt;&nbsp;0.001). LDL‑C and other lipid parameters returned to baseline within 12 weeks after discontinuation of Repatha at the beginning of OSLER or OSLER-2 without evidence of rebound.</p><p>&nbsp;</p><p>TAUSSIG was a multicentre, open-label, 5-year extension study to assess the long-term safety and efficacy of Repatha, as an adjunct to other lipid-lowering therapies, in patients with severe familial hypercholesterolaemia (FH), including homozygous familial hypercholesterolaemia. A total of 194 severe familial hypercholesterolaemia (non-HoFH) patients and 106 homozygous familial hypercholesterolaemia patients enrolled in TAUSSIG. All patients in the study were initially treated with Repatha 420&nbsp;mg once monthly, except for those receiving lipid apheresis at enrolment who began with Repatha 420&nbsp;mg once every 2 weeks. Dose frequency in non-apheresis patients could be titrated up to 420&nbsp;mg once every 2 weeks based on LDL‑C response and PCSK9 levels. Long-term use of Repatha demonstrated a sustained treatment effect as evidenced by reduction of LDL-C in patients with severe familial hypercholesterolaemia (non-HoFH) (see table 5).</p><p>&nbsp;</p><p>Changes in other lipid parameters (TC, ApoB, non-HDL-C, TC/HDL-C, and ApoB/ApoA1) also demonstrated a sustained effect of long-term Repatha administration in patients with severe familial hypercholesterolaemia (non-HoFH).</p><p>&nbsp;</p><p><strong>Table 5. Effect of evolocumab on LDL-C in patients with severe familial hypercholesterolaemia (non-HoFH)</strong><strong> &ndash; mean</strong><strong> percent change from baseline to OLE week 216 (and associated 95% CI)</strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:102%"><tbody><tr><td><p>Patient population</p><p>(N)</p></td><td><p>OLE week&nbsp;12</p><p>(n&nbsp;=&nbsp;191)</p></td><td><p>OLE week&nbsp;24</p><p>(n&nbsp;=&nbsp;191)</p></td><td><p>OLE week&nbsp;36</p><p>(n&nbsp;=&nbsp;187)</p></td><td><p>OLE week&nbsp;48</p><p>(n&nbsp;=&nbsp;187)</p></td><td><p>OLE week&nbsp;96</p><p>(n&nbsp;=&nbsp;180)</p></td><td><p>OLE week&nbsp;144</p><p>(n&nbsp;=&nbsp;180)</p></td><td><p>OLE week&nbsp;192</p><p>(n&nbsp;=&nbsp;147)</p></td><td><p>OLE week&nbsp;216</p><p>(n&nbsp;=&nbsp;96)</p></td></tr><tr><td><p>Severe FH (non‑HoFH) (N&nbsp;=&nbsp;194)</p></td><td><p>-54.9</p><p>(-57.4, -52.4)</p></td><td><p>-54.1</p><p>(-57.0, -51.3)</p></td><td><p>-54.7</p><p>(-57.4, -52.0)</p></td><td><p>-56.9</p><p>(-59.7, -54.1)</p></td><td><p>-53.3</p><p>(-56.9, -49.7)</p></td><td><p>-53.5</p><p>(-56.7, -50.2)</p></td><td><p>-48.3</p><p>(-52.9, -43.7)</p></td><td><p>-47.2</p><p>(-52.8, -41.5)</p></td></tr></tbody></table><p>Key: OLE = open-label extension, N (n) = Number of evaluable patients (N) and patients with observed LDL-C values at specific scheduled visit (n) in the severe familial hypercholesterolaemia (non-HoFH) final analysis set.</p><p>&nbsp;</p><p><u>Treatment of heterozygous familial hypercholesterolaemia in paediatric patients</u></p><p>&nbsp;</p><p>HAUSER-RCT was a randomized, multicentre, placebo-controlled, double‑blind, parallel‑group, 24‑week trial in 158 paediatric patients aged 10 to &lt;&nbsp;18 years with heterozygous familial hypercholesterolaemia. Patients were required to be on a low-fat diet and must have been receiving optimized background lipid-lowering therapy (statin at optimal dose, not requiring up titration). Enrolled patients were randomised in a 2:1 ratio to receive 24&nbsp;weeks of subcutaneous once monthly 420&nbsp;mg Repatha or placebo.</p><p>&nbsp;</p><p>The primary efficacy endpoint in this trial was percent change from baseline to week 24 in LDL-C. The difference between Repatha and placebo in mean percent change in LDL‑C from baseline to week 24 was 38%&nbsp;(95% CI: 45%, 31%; p&nbsp;&lt;&nbsp;0.0001). The least squares mean Standard Error (SE) reduction (p&nbsp;&lt;&nbsp;0.0001) in LDL-C from baseline at week&nbsp;24 was 44% (2%) in the Repatha group and 6% (3%) in the placebo group. Mean absolute LDL-C values at week&nbsp;24 were 104&nbsp;mg/dL in the Repatha group and 172&nbsp;mg/dL in the placebo group. Reductions in LDL-C were observed by the first post-baseline assessment at the week&nbsp;12 time point and were maintained throughout the trial.</p><p>&nbsp;</p><p>The secondary endpoint of this trial was mean percent change from baseline to weeks&nbsp;22 and 24 in LDL‑C, where week&nbsp;22 reflects the peak and week 24 the trough of the subcutaneous once monthly dosing interval, and provides information about the time-averaged effect of Repatha therapy over the entire dosing interval. The least squares mean treatment difference between Repatha and placebo in mean percent change in LDL‑C from baseline to the mean of week&nbsp;22 and week&nbsp;24 was 42% (95%&nbsp;CI: 48%, 36%; p&nbsp;&lt;&nbsp;0.0001). For additional results, see table 6.</p><p>&nbsp;</p><p>Table&nbsp;6. Treatment effects of Repatha compared with placebo in paediatric patients with heterozygous familial hypercholesterolaemia &ndash; mean percent change from baseline to week&nbsp;24 (%,&nbsp;95% CI)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:609px"><thead><tr><td><p>Study</p></td><td><p>Dose regimen</p></td><td><p>LDL-C</p><p>(%)</p></td><td><p>Non-HDL-C</p><p>(%)</p></td><td><p>ApoB</p><p>(%)</p></td><td><p>TC/<br />HDL-C Ratio</p><p>(%)</p></td><td><p>ApoB/<br />ApoA1 Ratio</p><p>(%)</p></td></tr></thead><tbody><tr><td><p>HAUSER-RCT (HeFH Paediatric Patients)</p></td><td><p>420&nbsp;mg QM (N&nbsp;=&nbsp;104)</p></td><td><p>-38.3</p><p>(-45.5, -31.1)</p></td><td><p>-35.0</p><p>(-41.8, -28.3)</p></td><td><p>-32.5</p><p>(-38.8, -26.1)</p></td><td><p>-30.3</p><p>(-36.4, -24.2)</p></td><td><p>-36.4</p><p>(-43.0, -29.8)</p></td></tr></tbody></table><p>QM = monthly (subcutaneous); CI = Confidence Interval; LDL-C = low density lipoprotein cholesterol; HDL‑C&nbsp;= high density lipoprotein cholesterol; ApoB = apolipoprotein B; ApoA1 = apolipoprotein A1, TC = total cholesterol</p><p>All adjusted p-values &lt;0.0001</p><p>N = number of patients randomised and dosed in the full analysis set.</p><p>&nbsp;</p><p>HAUSER‑OLE was an open‑label, single‑arm, multicentre, 80&nbsp;week study of Repatha in 150&nbsp;paediatric patients aged 10&nbsp;to&nbsp;17&nbsp;years with HeFH that rolled‑over from HAUSER-RCT and enrolled 13&nbsp;<em>de&nbsp;novo</em> paediatric HoFH patients. Patients had to be on a low‑fat diet and receiving background lipid‑lowering therapy. All HeFH patients in this study received 420&nbsp;mg Repatha subcutaneously once monthly (median exposure duration: 18.4&nbsp;months). The mean (SE) percent changes in calculated LDL‑C from baseline were: ‑44.4%&nbsp;(1.7%) at week&nbsp;12, ‑41.0%&nbsp;(2.1%) at week&nbsp;48, and ‑35.2%&nbsp;(2.5%) at week 80.</p><p>The mean (SE) percent change from baseline to week 80 in other lipid endpoints were: ‑32.1%&nbsp;(2.3%)&nbsp;non‑HDL‑C, ‑25.1%&nbsp;(2.3%)&nbsp;ApoB, ‑28.5%&nbsp;(2.0%)&nbsp;TC/HDL‑C ratio, ‑30.3%&nbsp;(2.2%)&nbsp;ApoB/ApoA1 ratio, and ‑24.9%&nbsp;(1.9%)&nbsp;TC.</p><p>&nbsp;</p><p><u>Treatment of homozygous familial hypercholesterolaemia</u></p><p><u>&nbsp;</u></p><p>TESLA was an international, multicentre, double-blind, randomised, placebo-controlled 12-week study in 49 homozygous familial hypercholesterolaemia patients aged 12 to 65 years. Repatha 420&nbsp;mg once monthly, as an adjunct to other lipid-lowering therapies (e.g., statins, bile-acid sequestrants), significantly reduced LDL‑C and ApoB at week 12 compared with placebo (p&nbsp;&lt;&nbsp;0.001) (see table 7). Changes in other lipid parameters (TC, non-HDL-C, TC/HDL-C, and ApoB/ApoA1) also demonstrated a treatment effect of Repatha administration in patients with homozygous familial hypercholesterolaemia.</p><p>&nbsp;</p><p><strong>Table 7. Treatment effects of evolocumab compared with placebo in patients with homozygous familial hypercholesterolaemia - mean percent change from baseline to week 12 (%, 95% CI)</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Study</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>LDL-C</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Non-HDL-C</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>ApoB</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>TC</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Lp(a)</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>VLDL-C</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>HDL-C</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>TG</strong></p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>TC/</strong></p><p><strong>HDL-C ratio</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>ApoB/</strong></p><p><strong>ApoA1 ratio</strong></p><p><strong>%</strong></p></td></tr><tr><td><p>TESLA</p><p>(HoFH)</p></td><td style="vertical-align:top"><p>420&nbsp;mg QM</p><p>(N&nbsp;=&nbsp;33)</p></td><td><p>-32<sup>b</sup></p><p>(‑45, ‑19)</p></td><td><p>-30<sup>a</sup></p><p>(‑42, ‑18)</p></td><td><p>-23<sup>b</sup></p><p>(‑35, ‑11)</p></td><td><p>-27<sup>a</sup></p><p>(‑38, ‑16)</p></td><td><p>-12</p><p>(‑25, 2)</p></td><td><p>-44</p><p>(‑128, 40)</p></td><td><p>-0.1</p><p>(‑9, 9)</p></td><td><p>0.3</p><p>(‑15, 16)</p></td><td><p>-26<sup>a</sup></p><p>(‑38, ‑14)</p></td><td><p>-28<sup>a</sup></p><p>(‑39, ‑17)</p></td></tr></tbody></table><p>Key: HoFH = homozygous familial hypercholesterolaemia, QM = once monthly, <sup>a</sup> nominal p value &lt;&nbsp;0.001 when compared with placebo, <sup>b</sup> p value &lt;&nbsp;0.001 when compared with placebo.</p><p>&nbsp;</p><p><u>Long-term efficacy in </u><u>homozygous familial hypercholesterolaemia</u></p><p>&nbsp;</p><p>In TAUSSIG, long-term use of Repatha demonstrated a sustained treatment effect as evidenced by reduction of LDL-C of approximately 20% to 30% in patients with homozygous familial hypercholesterolaemia not on apheresis and approximately 10% to 30% in patients with homozygous familial hypercholesterolaemia on apheresis (see table 8). Changes in other lipid parameters (TC, ApoB, non-HDL-C, TC/HDL-C, and ApoB/ApoA1) also demonstrated a sustained effect of long-term Repatha administration in patients with homozygous familial hypercholesterolaemia. Reductions in LDL-C and changes in other lipid parameters in 14 adolescent patients (aged &ge;&nbsp;12 to &lt;&nbsp;18 years) with homozygous familial hypercholesterolaemia are comparable to those in the overall population of patients with homozygous familial hypercholesterolaemia.</p><p><u>&nbsp;</u></p><p><strong>Table 8. </strong><strong>Effect of evolocumab on LDL-C in patients with homozygous familial hypercholesterolaemia</strong><strong> - mean percent change from baseline to OLE week 216</strong><strong> (and associated 95% CI)</strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Patient</p><p>population (N)</p></td><td><p>OLE week 12</p></td><td><p>OLE week 24</p></td><td><p>OLE week 36</p></td><td><p>OLE week 48</p></td><td><p>OLE week 96</p></td><td><p>OLE week 144</p></td><td><p>OLE week 192</p></td><td><p>OLE week 216</p></td></tr><tr><td><p>HoFH</p><p>(N&nbsp;=&nbsp;106)</p></td><td><p>-21.2</p><p>(-26.0, -16.3)</p><p>(n&nbsp;=&nbsp;104)</p></td><td><p>-21.4</p><p>(-27.8, -15.0)</p><p>(n&nbsp;=&nbsp;99)</p></td><td><p>-27.0</p><p>(-32.1, -21.9)</p><p>(n&nbsp;=&nbsp;94)</p></td><td><p>-24.8</p><p>(-31.4, -18.3)</p><p>(n&nbsp;=&nbsp;93)</p></td><td><p>-25.0</p><p>(-31.2, -18.8)</p><p>(n&nbsp;=&nbsp;82)</p></td><td><p>-27.7</p><p>(-34.9, -20.5)</p><p>(n&nbsp;=&nbsp;79)</p></td><td><p>-27.4</p><p>(-36.9, -17.8)</p><p>(n&nbsp;=&nbsp;74)</p></td><td><p>-24.0</p><p>(-34.0, -14.0)</p><p>(n&nbsp;=&nbsp;68)</p></td></tr><tr><td><p>Non‑apheresis</p><p>(N&nbsp;=&nbsp;72)</p></td><td><p>-22.7</p><p>(-28.1, -17.2)</p><p>(n&nbsp;=&nbsp;70)</p></td><td><p>-25.8</p><p>(-33.1, -18.5)</p><p>(n&nbsp;=&nbsp;69)</p></td><td><p>-30.5</p><p>(-36.4, -24.7)</p><p>(n&nbsp;=&nbsp;65)</p></td><td><p>-27.6</p><p>(-35.8, -19.4)</p><p>(n&nbsp;=&nbsp;64)</p></td><td><p>-23.5</p><p>(-31.0, -16.0)</p><p>(n&nbsp;=&nbsp;62)</p></td><td><p>-27.1</p><p>(-35.9, -18.3)</p><p>(n&nbsp;=&nbsp;60)</p></td><td><p>-30.1</p><p>(-37.9, -22.2)</p><p>(n&nbsp;=&nbsp;55)</p></td><td><p>-23.4</p><p>(-32.5, -14.2)</p><p>(n&nbsp;=&nbsp;50)</p></td></tr><tr><td><p>Apheresis</p><p>(N&nbsp;=&nbsp;34)</p></td><td><p>-18.1</p><p>(-28.1, -8.1)</p><p>(n&nbsp;=&nbsp;34)</p></td><td><p>-11.2</p><p>(-24.0, 1.7)</p><p>(n&nbsp;=&nbsp;30)</p></td><td><p>-19.1</p><p>(-28.9, -9.3)</p><p>(n&nbsp;=&nbsp;29)</p></td><td><p>-18.7</p><p>(-29.5, -7.9)</p><p>(n&nbsp;=&nbsp;29)</p></td><td><p>-29.7</p><p>(-40.6, -18.8)</p><p>(n&nbsp;=&nbsp;20)</p></td><td><p>-29.6</p><p>(-42.1, -17.1)</p><p>(n&nbsp;=&nbsp;19)</p></td><td><p>-19.6</p><p>(-51.2, 12.1)</p><p>(n&nbsp;=&nbsp;19)</p></td><td><p>-25.9</p><p>(-56.4, 4.6)</p><p>(n&nbsp;=&nbsp;18)</p></td></tr></tbody></table><p>Key: OLE = open-label extension, N (n) = Number of evaluable patients (N) and patients with observed LDL values at specific schedule visit (n) in the HoFH final analysis set.</p><p>HAUSER-OLE was an open‑label, single‑arm, multicentre, 80‑week trial in 12 HoFH subjects to evaluate the safety, tolerability and efficacy of Repatha for LDL-C reduction in paediatric patients from aged &ge;&nbsp;10 to &lt;&nbsp;18 years of age with homozygous familial hypercholesterolaemia. Patients had to be on a low-fat diet and receiving background lipid-lowering therapy. All patients in the study received 420&nbsp;mg Repatha subcutaneously once monthly. Median (Q1, Q3) LDL-C at baseline was 398 (343, 475)&nbsp;mg/dL. The median (Q1, Q3) percent change in LDL-C from baseline to week&nbsp;80 was ‑14% (‑41,&nbsp;4). Reductions in LDL-C were observed by the first assessment at week&nbsp;12 and was maintained throughout the trial, median (Q1, Q3) reductions ranging between 12% (-3, 32) and 15% (‑4, 39). For additional results, please see table&nbsp;9.</p><p>&nbsp;</p><p>Table&nbsp;9. Treatment effects of evolocumab compared with placebo in patients with homozygous familial hypercholesterolaemia &ndash; median (Q1, Q3) percent change from baseline to week&nbsp;80</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td><p>Study</p></td><td><p>Dose regimen</p></td><td><p>LDL-C</p><p>(%)</p></td><td><p>Non-HDL-C</p><p>(%)</p></td><td><p>ApoB</p><p>(%)</p></td><td><p>TC/<br />HDL-C Ratio</p><p>(%)</p></td><td><p>ApoB/<br />ApoA1 Ratio</p><p>(%)</p></td></tr></thead><tbody><tr><td><p>HAUSER-OLE (HoFH Paediatric Patients)</p></td><td><p>420&nbsp;mg QM (N&nbsp;=&nbsp;12)</p></td><td><p>-14.3</p><p>(-40.6, 3.5)</p></td><td><p>-13</p><p>(-40.7, 2.7)</p></td><td><p>-19.1</p><p>(-33.3, 11.6)</p></td><td><p>-3.7</p><p>(-41.6, 7.6)</p></td><td><p>-3</p><p>(-35.7, 9.3)</p></td></tr></tbody></table><p>QM = monthly (subcutaneous); LDL-C = low density lipoprotein cholesterol; HDL-C = high density lipoprotein cholesterol; ApoB = apolipoprotein B; ApoA1 = apolipoprotein A1, TC = total cholesterol</p><p>N = number of patients randomised and dosed in the interim analysis set.</p><p>&nbsp;</p><p><u>Effect on atherosclerotic disease burden</u></p><p><u>&nbsp;</u></p><p>The effects of Repatha 420&nbsp;mg once monthly on atherosclerotic disease burden, as measured by intravascular ultrasound (IVUS), were evaluated in a 78-week double-blind, randomised, placebo‑controlled study in 968 patients with coronary artery disease on a stable background of optimal statin therapy. Repatha reduced both percent atheroma volume (PAV; 1.01% [95% CI 0.64, 1.38], p&nbsp;&lt;&nbsp;0.0001) and total atheroma volume (TAV; 4.89&nbsp;mm<sup>3</sup> [95% CI 2.53, 7.25], p&nbsp;&lt;&nbsp;0.0001) compared with placebo. Atherosclerotic regression was observed in 64.3% (95% CI 59.6, 68.7) and 47.3% (95%&nbsp;CI&nbsp;42.6, 52.0) of patients who received Repatha or placebo respectively, when measured by PAV. When measured by TAV, atherosclerotic regression was observed in 61.5% (95% CI 56.7, 66.0) and 48.9% (95% CI 44.2, 53.7) of patients who received Repatha or placebo respectively. The study did not investigate the correlation between atherosclerotic disease regression and cardiovascular events.</p><p>&nbsp;</p><p>Effect on coronary atherosclerotic plaque morphology</p><p>&nbsp;</p><p>The effects of Repatha 420&nbsp;mg once monthly on coronary atherosclerotic plaques as assessed by optical coherence tomography (OCT), were evaluated in a 52‑week double-blind, randomised, placebo-controlled study including adult patients initiated within 7&nbsp;days of a non‑ST‑segment elevation acute coronary syndrome (NSTEACS) on maximally tolerated statin therapy. For the primary endpoint of absolute change in minimum FCT (fibrous cap thickness) in a matched segment of artery from baseline, least squares (LS) mean (95% CI) increased from baseline by 42.7&nbsp;&micro;m (32.4, 53.1) in the Repatha group and 21.5&nbsp;&micro;m (10.9, 32.1) in the placebo group, an additional 21.2&nbsp;&micro;m (4.7, 37.7) compared to placebo (p&nbsp;=&nbsp;0.015; 38% difference (p&nbsp;=&nbsp;0.041)). The reported secondary findings show treatment differences including change in mean minimum FCT (increase 32.5&nbsp;&micro;m (12.7, 52.4); p&nbsp;=&nbsp;0.016) and absolute change in maximum lipid arc (-26&deg; (-49.6, -2.4); p&nbsp;=&nbsp;0.041).</p><p>&nbsp;</p><p><u>Cardiovascular risk reduction in adults with established atherosclerotic cardiovascular disease </u></p><p>&nbsp;</p><p>The Repatha Outcomes Study (FOURIER) was a randomised, event-driven, double-blind study of 27,564 subjects, aged between 40 and 86 years (mean age 62.5 years), with established atherosclerotic CV disease; 81% had a prior MI event, 19% had a prior stroke event and 13% had peripheral arterial disease. Over 99% of patients were on moderate to high intensity statin and at least one other cardiovascular medicine such as anti-platelet agents, beta blockers, Angiotensin-Converting Enzyme (ACE) inhibitors, or angiotensin receptor blockers; median (Q1, Q3) baseline LDL-C was 2.4&nbsp;mmol/L (2.1, 2.8). Absolute CV risk was balanced between treatment groups, in addition to the index event all patients had at least 1 major or 2 minor CV risk factors; 80% had hypertension, 36% had diabetes mellitus, and 28% were daily smokers. Patients were randomised 1:1 to either Repatha (140&nbsp;mg every two weeks or 420&nbsp;mg once every month) or matching placebo; the mean duration of patient follow-up was 26&nbsp;months.</p><p>&nbsp;</p><p>A substantial reduction of LDL-C was observed throughout the study, with achieved median LDL-C ranges of 0.8 to 0.9&nbsp;mmol/L at each assessment; 25% of patients achieved a LDL-C concentration less than 0.5&nbsp;mmol/L. Despite the very low levels of LDL-C achieved, no new safety issues were observed (see section 4.8); the frequencies of new onset diabetes and cognitive events were comparable in patients who achieved LDL-C levels &lt;&nbsp;0.65&nbsp;mmol/L and those with higher LDL-C.</p><p>&nbsp;</p><p>Repatha significantly reduced the risk of cardiovascular events defined as the composite of time to first CV death, MI, stroke, coronary revascularisation, or hospitalisation for unstable angina (see&nbsp;table&nbsp;10); the Kaplan-Meier curves for the primary and key secondary composite endpoints separated at approximately 5&nbsp;months (see figure 1 for the MACE three year Kaplan-Meier curve). The&nbsp;relative risk of the MACE composite (CV death, MI, or stroke) was significantly reduced by 20%. The treatment effect was consistent across all subgroups (including age, type of disease, baseline LDL-C, baseline statin intensity, ezetimibe use, and diabetes) and was driven by a reduction in the risk of myocardial infarction, stroke and coronary revascularisation; no significant difference was seen on cardiovascular or all-cause mortality however the study was not designed to detect such a difference.</p><p>&nbsp;</p><p><strong>Table 10. Effect of evolocumab on major cardiovascular events</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><thead><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo<br />(N = 13,780)<br />n (%)</strong></p></td><td style="vertical-align:bottom"><p><strong>Evolocumab<br />(N = 13,784)<br />n (%)</strong></p></td><td style="vertical-align:bottom"><p><strong>Hazard ratio<sup>a</sup><br />(95% CI)</strong></p></td><td style="vertical-align:bottom"><p><strong>p value<sup>b</sup></strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>MACE+ (composite of MACE, coronary revascularisation, or hospitalisation for unstable angina)</p></td><td style="vertical-align:top"><p>1,563 (11.34)</p></td><td style="vertical-align:top"><p>1,344 (9.75)</p></td><td style="vertical-align:top"><p>0.85 (0.79, 0.92)</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>MACE (composite of CV death, MI, or stroke)</p></td><td style="vertical-align:top"><p>1,013 (7.35)</p></td><td style="vertical-align:top"><p>816 (5.92)</p></td><td style="vertical-align:top"><p>0.80 (0.73, 0.88)</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular death</p></td><td style="vertical-align:top"><p>240 (1.74)</p></td><td style="vertical-align:top"><p>251 (1.82)</p></td><td style="vertical-align:top"><p>1.05 (0.88, 1.25)</p></td><td style="vertical-align:top"><p>0.62</p></td></tr><tr><td style="vertical-align:top"><p>All-cause mortality</p></td><td style="vertical-align:top"><p>426 (3.09)</p></td><td style="vertical-align:top"><p>444 (3.22)</p></td><td style="vertical-align:top"><p>1.04 (0.91, 1.19)</p></td><td style="vertical-align:top"><p>0.54</p></td></tr><tr><td style="vertical-align:top"><p>Myocardial infarction (fatal/non-fatal)</p></td><td style="vertical-align:top"><p>639 (4.64)</p></td><td style="vertical-align:top"><p>468 (3.40)</p></td><td style="vertical-align:top"><p>0.73 (0.65, 0.82)</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.0001<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Stroke (fatal/non-fatal)<sup> d</sup></p></td><td style="vertical-align:top"><p>262 (1.90)</p></td><td style="vertical-align:top"><p>207 (1.50)</p></td><td style="vertical-align:top"><p>0.79 (0.66, 0.95)</p></td><td style="vertical-align:top"><p>0.0101<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Coronary revascularisation</p></td><td style="vertical-align:top"><p>965 (7.00)</p></td><td style="vertical-align:top"><p>759 (5.51)</p></td><td style="vertical-align:top"><p>0.78 (0.71, 0.86)</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.0001<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Hospitalisation for unstable angina<sup>e</sup></p></td><td style="vertical-align:top"><p>239 (1.7)</p></td><td style="vertical-align:top"><p>236 (1.7)</p></td><td style="vertical-align:top"><p>0.99 (0.82, 1.18)</p></td><td style="vertical-align:top"><p>0.89</p></td></tr></tbody></table><p><sup>a</sup> Based on a Cox model stratified by the randomisation stratification factors collected via Interactive Voice Response System (IVRS).</p><p><sup>b</sup> 2-sided log-rank test stratified by randomisation stratification factors collected via IVRS.</p><p><sup>c</sup> Nominal significance.</p><p><sup>d</sup> The treatment effect on stroke was driven by a reduction in risk of ischaemic stroke;&nbsp;there was no effect on haemorrhagic or undetermined stroke.</p><p><sup>e</sup> Assessment of time to hospitalisation for unstable angina was <em>ad-hoc</em>.</p><p>&nbsp;</p><p><strong>Figure 1. Time to a MACE event (composite of CV death, MI, or stroke); 3-year Kaplan-Meier</strong></p><p>&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="966" height="519" vspace="0" hspace="0" border="0" style="width:966px;height:519px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><u>&nbsp;</u></p><p>FOURIER-OLE (study 1 and study 2) consisted of two open-label, single-arm, multicenter, extension studies to evaluate the long-term safety, tolerability, and efficacy of Repatha in patients with established cardiovascular disease who completed the FOURIER study. Enrolled patients received Repatha 140&nbsp;mg every 2 weeks or 420&nbsp;mg once monthly for approximately 5 years and continued moderate- (22.2%) or high-intensity (74.8%) background statin therapy. Of the 5031 patients who received at least one dose of Repatha in study 1, 2,499 patients received Repatha and 2,532 patients received placebo in the FOURIER study. Of the 1,599 patients who received at least one dose of Repatha in study 2,&nbsp;854 patients received Repatha and 745 patients received placebo in the FOURIER study. Upon completion of study 1 and study 2, patients randomised to Repatha in the FOURIER study had up to 8.4 years (median 85.4 months) and 8.0 years of total Repatha exposure (median 80.2&nbsp;months) and patients randomised to placebo had up to 5.25 years (median 60.0 months) and 4.9 years of total Repatha exposure (median 55.1 months), respectively.</p><p>&nbsp;</p><p>In study 1 and 2 combined, 72.4% (n&nbsp;=&nbsp;4,802) of patients achieved a lowest post-baseline LDL‑C&nbsp;&lt;&nbsp;25&nbsp;mg/dL (0.65&nbsp;mmol/L), 87.0% (n&nbsp;=&nbsp;5,765) of patients achieved an LDL‑C&nbsp;&lt;&nbsp;40&nbsp;mg/dL (1.03&nbsp;mmol/L), and 11.9% (n&nbsp;=&nbsp;792) of patients had an all post-baseline LDL‑C&nbsp;&ge;&nbsp;40&nbsp;mg/dL (1.03&nbsp;mmol/L). Of the patients who achieved post-baseline low LDL-C (&lt;&nbsp;25&nbsp;mg/dL or &lt;&nbsp;40&nbsp;mg/dL), the overall subject incidences of treatment emergent adverse events were 80.0% patients who achieved LDL-C &lt;&nbsp;25&nbsp;mg/dL and 82.7% in patients who achieved LDL-C &lt;&nbsp;40&nbsp;mg/dL compared to 85.0% in patients with LDL-C &ge;&nbsp;40&nbsp;mg/dL. The overall subject incidences of serious treatment emergent adverse events were 37.7% in patients who achieved LDL-C &lt;&nbsp;25&nbsp;mg/dL and 40.0% in patients who achieved LDL-C &lt;&nbsp;40&nbsp;mg/dL compared to 41.5% in patients with LDL-C &ge;&nbsp;40&nbsp;mg/dL.</p><p>&nbsp;</p><p>The mean percent reduction from baseline in LDL-C was stable during the OLE study period and ranged from 53.4% to 59.1% for study 1 and 62.5% to 67.2% for study 2, regardless of the patient&rsquo;s original randomised treatment group in the FOURIER study. This appears to translate into a numerically lower subject incidence rate of adjudicated exploratory CV endpoints of the composite of CV death, MI and stroke for patients who had received Repatha in both the FOURIER and FOURIER OLE studies compared with patients who had received placebo in the FOURIER study and Repatha in the FOURIER OLE studies.</p><p>&nbsp;</p><p>Overall, no new safety findings were identified in these studies.</p><p><u>&nbsp;</u></p><p><u>Effect on LDL-C during acute phase of Acute Coronary Syndromes (ACS)</u></p><p><u>&nbsp;</u></p><p>EVOPACS was a single country, multicentre, double-blind, randomised, placebo-controlled, 8-week study on 308 ACS patients with evolocumab initiated in-hospital within 24 to 72 hours of presentation.</p><p>&nbsp;</p><p>If patients were not on a statin or were on statin treatment other than atorvastatin 40&nbsp;mg prior to screening, this was stopped and atorvastatin 40&nbsp;mg once daily was initiated. Randomisation was stratified by study centre and presence of stable statin treatment within &ge;&nbsp;4 weeks prior to enrolment. Most subjects (241 [78%]) were not on stable statin treatment for &ge;&nbsp;4 weeks prior to screening and most (235 [76%]) were not taking a statin at baseline. By week 4, 281 (97%) subjects were receiving high-intensity statins. Evolocumab 420&nbsp;mg once monthly significantly reduced LDL-C from baseline to week 8 compared with placebo (p&nbsp;&lt;&nbsp;0.001). The mean (SD) reduction in calculated LDL-C from baseline at week 8 was 77.1% (15.8%) in the evolocumab group and 35.4% (26.6%) in the placebo group with a least squares (LS) mean difference (95% CI) of 40.7% (36.2%, 45.2%). Baseline LDL-C values were 3.61&nbsp;mmol/L (139.5&nbsp;mg/dL) in the evolocumab group and 3.42&nbsp;mmol/L (132.2&nbsp;mg/dL) in the placebo group. LDL-C reductions in this study were consistent with previous studies where evolocumab was added to stable lipid-lowering therapy as demonstrated by on-treatment LDL-C levels at week 8 in this study (reflecting steady-state effect of high-intensity statin in both treatment arms) of 0.79&nbsp;mmol/L (30.5&nbsp;mg/dL) and 2.06&nbsp;mmol/L (79.7&nbsp;mg/dL) in the evolocumab plus atorvastatin and the placebo plus atorvastatin groups, respectively.</p><p><strong>&nbsp;</strong></p><p>The effects of evolocumab in this patient population were consistent with those observed in previous studies in evolocumab clinical development program and no new safety concerns were noted.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption and distribution</u></p><p>&nbsp;</p><p>Following a single subcutaneous dose of 140&nbsp;mg or 420&nbsp;mg evolocumab administered to healthy adults, median peak serum concentrations were attained in 3 to 4 days. Administration of single subcutaneous dose of 140&nbsp;mg resulted in a C<sub>max</sub> mean (SD) of 13.0&nbsp;(10.4)&nbsp;&micro;g/mL and AUC<sub>last</sub> mean (SD) of 96.5&nbsp;(78.7)&nbsp;day&bull;&micro;g/mL. Administration of single subcutaneous dose 420&nbsp;mg resulted in a C<sub>max</sub> mean (SD) of 46.0&nbsp;(17.2)&nbsp;&micro;g/mL and AUC<sub>last</sub> mean (SD) of 842&nbsp;(333)&nbsp;day&bull;&micro;g/mL. Three subcutaneous 140&nbsp;mg doses were bioequivalent to a single subcutaneous 420&nbsp;mg dose. The absolute bioavailability after SC dosing was determined to be 72% from pharmacokinetic models.</p><p>&nbsp;</p><p>Following a single 420&nbsp;mg evolocumab intravenous dose, the mean (SD) steady-state volume of distribution was estimated to be 3.3&nbsp;(0.5)&nbsp;L, suggesting evolocumab has limited tissue distribution.</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Evolocumab is composed solely of amino acids and carbohydrates as native immunoglobulin and is unlikely to be eliminated via hepatic metabolic mechanisms. Its metabolism and elimination are expected to follow the immunoglobulin clearance pathways, resulting in degradation to small peptides and individual amino acids.</p><p><strong>&nbsp;</strong></p><p><u>Elimination</u></p><p>&nbsp;</p><p>Evolocumab was estimated to have an effective half-life of 11 to 17 days.</p><p>&nbsp;</p><p>In patients with primary hypercholesterolaemia or mixed dyslipidaemia on high dose statin, the systemic exposure of evolocumab was slightly lower than in subjects on low-to-moderate dose statin (the ratio of AUC<sub>last</sub> 0.74 [90% CI 0.29, 1.9]). An approximately 20% increase in the clearance is in part mediated by statins increasing the concentration of PCSK9 which did not adversely impact the pharmacodynamic effect of evolocumab on lipids. Population pharmacokinetic analysis indicated no appreciable differences in evolocumab serum concentrations in hypercholesterolaemic patients (non‑familial hypercholesterolaemia or familial hypercholesterolaemia) taking concomitant statins.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>&nbsp;</p><p>Following a single 420&nbsp;mg intravenous dose, the mean (SD) systemic clearance was estimated to be 12&nbsp;(2)&nbsp;mL/hr. In clinical studies with repeated subcutaneous dosing over 12 weeks, dose proportional increases in exposure were observed with dose regimens of 140&nbsp;mg and greater. An approximate two to three-fold accumulation was observed in trough serum concentrations (C<sub>min</sub> (SD) 7.21 (6.6)) following 140&nbsp;mg doses every 2 weeks or following 420&nbsp;mg doses administered monthly (C<sub>min</sub> (SD) 11.2 (10.8)), and serum trough concentrations approached steady-state by 12 weeks of dosing.</p><p>&nbsp;</p><p>No time dependent changes were observed in serum concentrations over a period of 124 weeks.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>No dose adjustment is necessary in patients with renal impairment. Data from the evolocumab clinical trials did not reveal a difference in pharmacokinetics of evolocumab in patients with mild or moderate renal impairment relative to non-renally impaired patients.</p><p>In a clinical trial of 18 patients with either normal renal function (estimated glomerular filtration rate</p><p>[eGFR] &ge; 90 mL/min/1.73 m<sup>2</sup> n = 6), severe renal impairment (eGFR 15 to 29 mL/min/1.73 m<sup>2</sup>,</p><p>n = 6), or end-stage renal disease (ESRD) receiving haemodialysis (n = 6), exposure to unbound</p><p>evolocumab as assessed by C<sub>max</sub> after a single 140 mg subcutaneous dose was decreased by 30% in</p><p>patients with severe renal impairment and by 45% in patients with ESRD receiving haemodialysis.</p><p>Exposure as assessed by AUClast was decreased by approximately 24% in patients with severe renal</p><p>impairment and by approximately 45% in patients with ESRD receiving haemodialysis. The exact</p><p>mechanism of PK differences is unknown; however, differences in body weight could not explain</p><p>these differences. Some factors including small sample size and large inter-subject variability should</p><p>be considered when interpreting the results. The pharmacodynamics and safety of evolocumab in</p><p>patients with severe renal impairment and ESRD were similar to patients with normal renal function,</p><p>and there were no clinically meaningful differences in LDL-C lowering. Therefore, no dose</p><p>adjustments are necessary in patients with severe renal impairment or ESRD receiving haemodialysis.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>No dose adjustment is necessary in patients with mild hepatic impairment (Child-Pugh class A). Single 140&nbsp;mg subcutaneous doses of evolocumab were studied in 8 patients with mild hepatic impairment, 8&nbsp;patients with moderate hepatic impairment and 8 healthy subjects. The exposure to evolocumab was found to be approximately 40-50% lower compared to healthy subjects. However, baseline PCSK9 levels and the degree and time course of PCSK9 neutralisation were found to be similar between patients with mild or moderate hepatic impairment and healthy volunteers. This resulted in similar time course and extent of absolute LDL-C lowering. Evolocumab has not been studied in patients with severe hepatic impairment (Child-Pugh class C) (see section 4.4).</p><p>&nbsp;</p><p><u>Body weight </u></p><p><u>&nbsp;</u></p><p>Body weight was a significant covariate in population PK analysis impacting evolocumab trough concentrations, however there was no impact on LDL-C reduction. Following repeat subcutaneous administration of 140&nbsp;mg every 2 weeks, the 12-week trough concentrations were 147% higher and 70% lower in patients of 69&nbsp;kg and 93&nbsp;kg respectively, than that of the typical 81&nbsp;kg subject. Less impact from body weight was seen with repeated subcutaneous evolocumab 420&nbsp;mg monthly doses.</p><p>&nbsp;</p><p><u>Other special populations</u></p><p>&nbsp;</p><p>Population pharmacokinetic analyses suggest that no dose adjustments are necessary for age, race or gender. The pharmacokinetics of evolocumab were influenced by body weight without having any notable effect on LDL-C lowering. Therefore, no dose adjustments are necessary based on body weight.</p><p>&nbsp;</p><p>The pharmacokinetics of Repatha were evaluated in 103 paediatric patients aged &ge;&nbsp;10 to &lt;&nbsp;18&nbsp;years with heterozygous familial hypercholesterolaemia (HAUSER-RCT). Following subcutaneous administration of 420&nbsp;mg Repatha once monthly, mean (SD) trough serum concentrations were 22.4 (14.7)&nbsp;mcg/mL, 64.9 (34.4)&nbsp;mcg/mL and 25.8 (19.2)&nbsp;mcg/mL over the Week&nbsp;12, Week&nbsp;22 and Week&nbsp;24 time points, respectively. The pharmacokinetics of Repatha were evaluated in 12 paediatric patients aged &ge;&nbsp;10 to &lt;&nbsp;18 years with homozygous familial hypercholesterolaemia (HAUSER-OLE). Following subcutaneous administration of 420&nbsp;mg Repatha once monthly, mean (SD) serum trough concentrations were 20.3 (14.6)&nbsp;mcg/mL and 17.6 (28.6)&nbsp;mcg/mL at Week&nbsp;12 and Week&nbsp;80, respectively.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Evolocumab was not carcinogenic in hamsters at exposures much higher than patients receiving evolocumab at 420&nbsp;mg once monthly. The mutagenic potential of evolocumab has not been evaluated.</p><p>&nbsp;</p><p>In hamsters and cynomolgus monkeys at exposures much higher than patients receiving 420&nbsp;mg evolocumab once monthly, no effect on male or female fertility was observed.</p><p>&nbsp;</p><p>In cynomolgus monkeys at exposures much higher than patients receiving 420&nbsp;mg evolocumab once monthly, no effects on embryo-foetal or postnatal development (up to 6&nbsp;months of age) were observed.</p><p><strong>&nbsp;</strong></p><p>Apart from a reduced T-cell Dependent Antibody Response in cynomolgus monkeys immunised with keyhole limpet haemocyanin (KLH) after 3&nbsp;months of treatment with evolocumab, no adverse effects were observed in hamsters (up to 3&nbsp;months) and cynomolgus monkeys (up to 6&nbsp;months) at exposures much higher than patients receiving evolocumab at 420&nbsp;mg once monthly. The intended pharmacological effect of decreased serum LDL-C and total cholesterol were observed in these studies and was reversible upon cessation of treatment.</p><p>&nbsp;</p><p>In combination with rosuvastatin for 3&nbsp;months, no adverse effects were observed in cynomolgus monkeys at exposures much higher than patients receiving 420&nbsp;mg evolocumab once monthly. Reductions in serum LDL-C and total cholesterol were more pronounced than observed previously with evolocumab alone, and were reversible upon cessation of treatment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Proline: 25&nbsp;mg</p><p>Glacial acetic acid: 1.2&nbsp;mg</p><p>Polysorbate 80: 0.10&nbsp;mg</p><p>Sodium hydroxide (for pH adjustment)</p><p>Water for injections</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C). Do not freeze.</p><p>&nbsp;</p><p>Store in the original carton in order to protect from light.</p><p>&nbsp;</p><p>If removed from the refrigerator, Repatha may be stored at room temperature (up to 25&deg;C) in the original carton and must be used within 1 month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>One mL solution in a single use pre-filled pen made from type I glass with stainless steel 27 gauge needle.</p><p>&nbsp;</p><p>The needle cover of the pre-filled pen is made from dry natural rubber (a derivative of latex, see section 4.4).</p><p>&nbsp;</p><p>Pack sizes of one, two, three pre-filled pens or multipacks containing 6 (3 packs of 2) pre-filled pens.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before administration, the solution should be inspected. The solution should not be injected if it contains particles, or is cloudy or discoloured. To avoid discomfort at the site of injection, the medicinal product should be allowed to reach room temperature (up to 25&deg;C) before injecting. The entire contents should be injected.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amgen Europe B.V.
Minervum 7061 
4817 ZK Breda
The Netherlands


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2023.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>